About CSL Behring
A commitment to patient need, regardless of patient numbers
CSL Behring is dedicated to developing and producing therapies for patients in need
no matter how rare the illness or how few patients are affected. In addition to
treating patients with Alpha-1–associated emphysema, our commitment to innovation
includes therapies for patients with:
- Hemophilia
- Von Willebrand disease
- Factor XIII deficiency
- Primary immunodeficiency disease
A global leader in plasma therapies
With over 60 years of experience in working with biotherapies, we have a unique
perspective on the challenges and opportunities associated with developing and manufacturing
plasma protein products. The rare nature of plasma disorders allows us to make true
connections with the people who suffer from them, and to understand their unique
needs and concerns. And this deep insight informs our development of innovative
therapies.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.